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"We absolutely must leave room for doubt or there is no progress and there
is no learning. There is no learning without having to pose a question. And
a question requires doubt."
Richard P. Feynman

Abstract
The survival of any human being is only possible with a highly specializedmusculoskele-
tal system that provides functional independence in terms of day-to-day activities. The
importance is underlined by the observation of declining functional abilities through loss
of muscle mass and strength in aging people. Physical impairment, and thus declining
independence, are major risk factors for adverse health outcomes with higher rates of
institutionalization and mortality. Postural instability and falls are feared complications
of old people, which are results of low skeletal muscle strength and function, also known
as sarcopenia. Changes of skeletal muscle during ageing have already been investi-
gated, nevertheless it is yet unclear, if skeletal muscle differs between sarcopenic and
non-sarcopenic patients.
To address this question, we took biopsies of the gluteus medius muscle from 20 pa-
tients, who underwent surgical intervention due to traumatic proximal femur fractures.
We employed immunohistochemical staining methods to reveal specifics of skeletal
muscle morphology. Additionally, we estimated physical performance with a question-
naire containing questions regarding activities of the daily living, measured handgrip
strength and blood levels of 25-hydroxyvitamin D, thyroid-stimulating hormone, total
protein and calcium. We used the definition provided by the European Working Group
on Sarcopenia in Older People to divide the study cohort into sarcopenic and non-
sarcopenic patients. Results revealed that with increasing age, the cross sectional area
of fast-twitching fibers declined, whereas the slow-twitching fibers seemed to be unaf-
fected. Also, when compared to relativemusclemass, we could show that lower skeletal
muscle mass did not correlate with the skeletal muscle fiber cross-sectional area. The
proportion of type I fibers was generally the highest throughout all patients, followed by
type IIa fibers and then type IIx fibers. Nevertheless, we could find no age-dependent
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trend in the proportion of fiber types. Additionally, we analyzed fiber size and proportion
between sarcopenic and non-sarcopenic patients, but we could not find any differences.
In sum, we found that aging skeletal muscle of our study cohort depicted morpho-
logic characteristics concordant to existing literature of different skeletal muscles (e.g.
vastus lateralis muscle), but skeletal muscle fibers from gluteus medius muscle of sar-
copenic patients were not different in size nor proportion compared to those of non-
sarcopenic people. We therefore concluded that sarcopenia was likely not caused by a
single mechanism in our study and thus, causes that lead to primary sarcopenia have
yet to be elucidated.
II
Zusammenfassung
DasÜberleben eines jedenMenschen ist nurmit Hilfe eines hoch spezialisiertenmusku-
loskelettalen Systemsmöglich, welches funktionale Unabhängigkeit im alltäglichen Leben
ermöglicht. Die Bedeutung wird durch die Beobachtung unterstrichen, dass die funk-
tionellen Fähigkeiten durch den Verlust von Muskelmasse und -kraft im Alter deutlich
abnehmen. Körperliche Einschränkungen und damit die schwindende Unabhängigkeit
stellen große Risiken für die Gesundheit dar und erhöhen sowohl die Rate an Kranken-
hausaufenthalten als auch dieMortalität. Posturale Instabilität und Stürze sind gefürchtete
Komplikationen des Alterns, welche durch den Verlust von Muskelkraft, auch Sarkope-
nie genannt, bedingt sind. Die Veränderungen von Skelettmuskel im Alter sind bisher in
vielen Belangen untersucht worden, dennoch ist bisher wenig darüber bekannt, welche
Unterschiede Skelettmuskel sarkopener Patienten im Vergleich mit Skelettmuskel nicht
sarkopener Patienten aufweist.
Um dieser Frage nachzugehen, sammelten wir Biopsien aus dem Musculus gluteus
medius von 20 Patienten, die sich zu dieser Zeit in der Behandlung wegen einer proxi-
malen Femurfraktur befanden. Wir wandten immunhistochemische Färbungen an, um
die Morphologie der Skelettmuskulatur zu untersuchen. Zusätzlich bewerteten wir die
körperliche Leistungsfähigkeit mittels eines Fragebogens mit Fragen, die auf Aktivitäten
des Alltagslebens gerichtet waren, maßen die Handkraft und die Blutwerte von Vitamin
D, Thyroid-stimulierendem Hormon, Gesamtprotein und Calcium. Wir benutzten die
Definition der European Working Group on Sarcopenia in Older People um die Studi-
enkohorte in sarkopene und nicht sarkopene Patienten aufzuteilen. Unsere Ergebnisse
zeigten, dass mit steigendem Alter die schnellen Muskelfasern in ihrer Gesamtgröße
abnehmen, wobei die langsamen Muskelfasern weniger beeinflusst zu sein scheinen.
Im Vergleich zur Muskelmasse der Probanden zeigte sich allerdings, dass die Größe
III
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der Muskelfasern nicht mit der Muskelmasse im Zusammenhang steht. Der Anteil an
Typ I Fasern an der Gesamtzahl war in allen Biopsien am größten, gefolgt von Typ IIa
und danach Typ IIx Fasern. Dennoch konnten wir keinen Zusammenhang zwischen
dem Alter und dem Anteil an Muskelfasern erkennen. Zusätzlich untersuchten wir die
Größe der Muskelfasern und den Anteil an der Gesamtzahl zwischen sarkopenen und
nicht sarkopenen Patienten. Wir konnten allerdings keinen signifikanten Unterschied
zwischen den beiden Gruppen feststellen.
Schlussendlich konnten wir herausfinden, dass die Größe der schnellen Typ IIa und
IIx Muskelfasern mit dem steigenden Alter abnimmt, was im Einklang mit der schon
existierenden Literatur bzgl. anderer Muskeltypen wie Musculus vastus lateralis steht.
Allerdings konnten wir keinen Unterschied zwischen sarkopenen und nicht sarkopenen
Patienten darstellen. Wir schließen daraus, dass die Gründe für Sarkopenie in unserer
Kohorte nicht auf eine einzelne Ursache zurückzuführen sind und das die Ursachen für
eine solche primäre Sarkopenie weiter untersucht werden müssen.
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Chapter 1
Introduction
1.1 The importance of locomotion
The survival of a species is only possible by consuming food as an energy source, by
repelling natural predators and by reproduction. All these aspects heavily rely on the
locomotion of the organism. Depending on the animal, themovements to suit these spe-
cific tasks are more or less complex. Functional independence in terms of breathing,
generating heat and maintaining health can only be sustained by a complex system
of muscles in most animals. Especially in higher organisms such as humans, social
participation plays a key role in day-to-day living, which also requires distinct sets of
muscles.
In humans, locomotion involves diverse kinds of movement and different parts of the
body, including limbs for walking, jumping and gripping, the neck to move the head, the
jaw and pharynx to chew and swallow food and facial muscles to make expressions. In
addition, not only does the execution of dynamic movements require muscles, but also
static tension to keep posture.
The importance of skeletal muscle can be seen by the proportion of muscle tissue in the
whole body. On average, around 40% of the body weight is made up of skeletal muscle
mass, containing 50 – 75% of all proteins and being responsible for 30 to 50% of all
protein turnover (Spargo et al., 1979; Frontera and Ochala, 2015). For maintaining the
integrity of the body, muscles demand a large amount of energy, which is stored inside
the muscle cells in form of glycogen. This storage is not only used by muscles, but
is also used to maintain a constant level of glucose in the blood, which is specifically
1
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needed by the neuronal system (Stump et al., 2006). These facts show that muscle
tissue is not only important for movement, but also plays an important role in the supply
of metabolic substrates for other organs (Wolfe, 2006).
By summarizing the diverse functions of skeletal muscles, it is easily imaginable that
loosing muscle mass and/or function poses a pivotal problem for the organism. Muscu-
lar diseases, as well as normal aging, cause complications to different extents. Patients
with muscular dystrophies, such as Duchenne or Becker, show a significantly reduced
life span, due to an early onset of advancing atrophy of skeletal muscles and ultimately
the failure of respiratory muscles. Additionally, loss of muscle mass through aging en-
tails a health risk, as low skeletal muscle mass is a major risk factor for higher mortality
(Srikanthan and Karlamangla, 2014).
1.2 Architecture of skeletal muscle tissue
1.2.1 Macroanatomy
Skeletal muscle is a well-defined tissue, consisting mainly of muscle fibers and little
surrounding connective tissue, in which a densely distinctive vascular network, inner-
vating axons and muscle-specific fibroblasts are embedded. Tendons connect muscles
and bones through myotendinous junctions and entheses, respectively, to transfer me-
chanical force over joints and thus generate locomotion. Most muscles are surrounded
by a firm layer of fascia. Underneath the fascia, the fiber is surrounded by the epimy-
sium, a layer of loose connective tissue, which also divides the muscle into fascicles
(Figure 1.1). The fascicles are each subdivided into muscle fibers by the endomysium.
Within this connective tissue, blood vessels form a densely packed capillary network
and nerves branch to innervate each individual muscle fiber and spindle. The mus-
cle fibers represent the majority of skeletal muscle cells that composed of a single cell
membrane, surrounded by a basal lamina. Muscle fibers contain myofibrils, the sar-
coplasmic reticulum, a network of mitochondria and multiple nuclei (Dahl et al., 2015;
Picard et al., 2013). The size of a healthy and young muscle depends mainly on the
number and the size of the muscle fibers and to a lesser degree on the amount of fat
and connective tissue between the fibers. However, with advanced age or in presence
2
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of myotendinous diseases, the amount of fat and connective tissue is decisively higher
(Emery, 2002; Brown and Hasser, 1996).
Figure 1.1: Structure of skeletal muscle.
(A) The whole muscle is surrounded by a layer of fascia and a layer of epimysium, which divides
the muscle into fascicles. (B-C) Each fascicle is subdivided into muscle fibers that contain the
contractile myofibrils. Myofibrils consist of overlaying thick myosin and thin actin filaments. (D)
Thick filaments hold several myosin heads that build cross-bridges with the actin filament. Thin
filaments are surrounded by troponin and tropomyosin (Sherwood, 2014).
1.2.2 Microanatomy
Within muscle fibers, myofibrils are densely packed and surrounded by sarcoplasmic
reticulum, which itself has connections to transverse tubules. The tubules are inver-
sions of the cell membrane, which create a large surface between the extracellular and
intracellular compartments and a net of mitochondria. Two tubules of the sarcoplasmic
3
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reticulum are accompanied by one transverse tubule, forming a triad orthogonal to the
myofibrils. The mitochondria are located underneath the cell membrane and between
the myofibrils (Figure 1.2).
As every muscle fiber is connected to only one neuromuscular junction, the large sur-
face is important for the fast and even transduction of the excitation potential provoked
by motor neurons (Slater, 2017). The myofibrils are long repetitive constructs consisting
of sarcomeres, which are myosin filaments overlapping with actin filaments. These are
the basic functional units of the contractile apparatus. The myosin filaments are able
to build cross-bridges with the actin filaments and move their heads by the use of ATP
and calcium (Figure 1.1, C-D). This generates a sliding movement against each other
and thus the contraction of the muscle (Kuo and Ehrlich, 2015).
1.2.3 Muscle physiology
Muscle cells normally do not act independently, but require an external stimulus to ini-
tiate their contraction, which is necessary for a reliable and very narrow coordination
between individual muscles and between muscle groups. Otherwise, a human body
could not perform any tasks that require coordinated movement in any kind.
Directly responsible for the stimulus are somatic motor neurons in the ventral horn of
the spinal cord. Each motor neuron has one axon that projects from the spinal cord
via distinct nerve bundles to the target skeletal muscles, where it branches and inner-
vates several muscle fibers. The amount of muscle fibers innervated by one motor
neuron depends on the muscle and can vary from less than hundred fibers per neu-
ron in extraocular and facial muscles to several hundreds of muscle fibers in soleus
and quadriceps femoris muscle (Torre, 1953; Christensen, 1959; Burke et al., 1974).
A neuron and its corresponding muscle fibers are known as motor units and represent
the most basic functional unit within a muscle, because action potentials of one motor
neuron trigger every innervated fiber simultaneously (Figure 1.3, A) (Fulton, 1931).
4
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Figure 1.2: Three dimensional representation of the tubule system inside a skeletal mus-
cle fiber.
The schematic representation of a skeletal muscle fiber depicts the three dimensional tubule
system within the fiber. The transversal tubules, which are inversions of the cell membrane
lie adjacent to two tubules of the sarcoplasmic reticulum, forming a triad. This network reaches
through thewholemuscle fiber. Additionally, rich deposits of mitochondria are scattered between
the myofibrils (Staff, 2014).
The motor neuron-derived action potentials reach the neuromuscular junction, a
specific synapse between neuronal and muscular cells (Figure 1.4). Vesicles in the
presynaptic terminal of the neuron fuse with the membrane and release acetylcholine
into the synaptic cleft, which binds to the postsynaptic ionotropic nicotinic acetylcholine
receptors (AChR). These ligand-gated ion channels then let cations pass through and
thus cause a cascade of opening voltage-dependent calcium channels throughout the
5
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Figure 1.3: Schematic concept of two motor units.
Panel (A) shows two motor units in a skeletal muscle. One motor neuron innervates several
skeletal muscle fibers of the same fiber type. Each skeletal muscle fiber is only innervated by
one motor neuron. Muscle fibers of one motor unit do not necessarily lie adjacent to each other,
but can intersect, which is responsible for the checkerboard-like distribution of fiber types within
a muscle cross-section. (B) A motor neuron in the ventral horn of the spinal cord innervates
skeletal muscle via an afferent axon and receives information about tension of muscle spindles
via dorsal root ganglia. This creates a monosynaptic circuit, which can quickly and efficiently
propagate information from the muscle spindle to the muscle.
transverse tubules and thereby depolarizing the muscle fiber. Dihydropyridine recep-
tors (DHPRs), specific calcium channels in the cell membrane, physically interact with
ryanodine receptors (RyRs) in the membrane of the sarcoplasmic reticulum directly ad-
jacent to the transverse tubules. DHPRs then open due to the depolarization of the
sarcolemma and open the RyRs themselves, which then release calcium stored within
the sarcoplasmic reticulum (Kuo and Ehrlich, 2015).
When calcium is released from the sarcoplasmic reticulum, calcium binds to tro-
ponin, a protein on the actin filaments. Following the binding, troponin exposes the
myosin binding site and allows myosin to establish a cross-bridge to the actin filament.
This connection dissociates when adenosine triphosphate (ATP) binds to the myosin
adenosinetriphosphatase (ATPase). ATP is then hydrolyzed into adenosine diphos-
phate (ADP) and phosphate (Pi), which generates a conformation change of the myosin
where the head swings to the next actin molecule of the filament and binds again. Phos-
phate is then released and the head performs a “power stroke” releasing the ADP. At this
point, new ATPmust be bound to release the myosin heads from the actin filaments, be-
6
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Figure 1.4: Illustration of a neuromuscular junction.
The figure shows a schematic display of a neuromuscular junction. Acetylcholine, which is
stored in presynaptic vesicles, is released into the synaptic cleft upon depolarization by an action
potential. Acetylcholine is then bound by the postsynaptic acetylcholine receptor (AChR) and
thus induces a cascadic depolarization of the sarcolemma. Voltage dependent dihydropyridine
receptors (DHPR) open sarcoplasmic ryanodine receptors (RyR), which then release calcium
into the sarcoplasm.
ginning a new cycle of the contraction mechanism (Figure 1.5). Afterwards, the calcium
gradient is reestablished by sarco/endoplasmatic reticulum calcium-ATPase (SERCA)
transporters.
The central nervous system does not only activate muscles, but also receives infor-
mation about the length and tension by the use of muscle spindles and Golgi tendon
organs. While muscle spindles are specific stretch receptors, which are located within
the muscle between the muscle fibers, Golgi tendon organs are stretch receptors within
the tendons. Both organs combined give information via afferent fibers of a nerve to the
7
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Figure 1.5: Excitation-contraction cycle sequence.
The figure shows the sequence of actions within skeletal muscle in the presence of stimulation
by a motor neuron. (A) The myosin head of the thick filament is tightly bound to the actin of the
thin filament. (B) This binding dissociates when the myosin head bind ATP. (C-D) ATP is then
hydrolyzed into ADP and Pi by the myosin ATPase. This leads to a confirmation change in the
myosin head, which then swings to another actin molecule. (E-F) Dissociation of ADP and Pi
lead to a change of confirmation and initializes a ‘power stroke’. Afterwards, myosin is again
tightly bound to actin. Adapted and modified form (Frontera and Ochala, 2015)
central nervous system about the position and contraction of muscles. Muscle spindles
and the Golgi tendon organs are innervated by sensory neurons situated in the dorsal
root ganglia, which send their axons through the dorsal horn of the spinal cord, where
they connect to the motor neurons of the corresponding muscle. This is a monosynaptic
8
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connection from the muscle spindle, respectively the Golgi tendon organ, through the
spinal root ganglion and the motor neuron to the same muscle (Figure 1.3, B) (Kröger,
2018; Sherrington, 1894). Both neurons are excitatory neurons and together have the
function of triggering a contraction when the muscle is stretched, an indispensable fea-
ture to prevent muscles, tendons and joints from injury.
This is the most basic functional unit of movement regulation. It is observable when
provoking stretch reflexes such as the patellar reflex or the ankle jerk reflex. In addition,
each neuron branches out to various other neurons and interneurons and receive ax-
ons from many other neurons, making the whole mechanism vastly more complex and
allowing simple monosynaptic reflexes to modulate muscle tension and contraction of
different muscle groups, lowering the tension in antagonizing muscles and even bring
up “primitive” reflexes such as walking or swimming.
1.2.4 Molecular biology
Myofibrils are connected to the cell membrane and proteins of the extracellular ma-
trix via a dystrophin-associated glycoprotein complex (DGC). These complex structures
contain a variety of proteins, such as dystrophin, dystroglycan and sarcoglycan. Dys-
trophin, a major protein of the DGC, and utrophin are directly connected to the actin
filaments of the myofibrils and are themselves anchored in the cell membrane through
sarcoglycan and dystroglycan, amongst others (Bhat et al., 2018). On the extracellular
side of the cell membrane, the DGC is connected to the lamina densa of the basement
membrane via laminin 2 (Figure 1.6). This connection allows the force generated by
the contractile organelles of the cell to be conducted through the DGCs, the myotendi-
nous junctions and the tendons finally to the bones (Townsend, 2014). The importance
of the DGCs can be observed in people whose proteins of the DGCs are genetically
compromised and are not fully functional as in various myopathies, such as Duchenne
or Becker muscular dystrophy (Hoffman et al., 1987).
The basal lamina of each muscle fiber also surrounds several satellite cells, which
are pre-mitotic stem cells of the muscle tissue, providing the cellular source of physio-
logical muscle hypertrophy and regeneration (Bareja et al., 2014). The myonuclei are
9
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Figure 1.6: Dystrophin-associated glycoprotein complex (DGC) in muscle fibers.
The Dystrophin-associated glycoprotein complex is a complex of several proteins within the
membrane of a skeletal muscle fiber, which interacts with various intra- and extracellular pro-
teins. Actin filaments are connected via utrophin and dystrophin with various proteins in the
sarcolemma. On the outside of the skeletal muscle fiber the DGC is linked via laminin to extra-
cellular collagen. This connection holds the sarcomeres in place and conducts the contracting
force to the whole muscle (Emery, 2002).
typically located at the periphery of the muscle cell below the cell membrane, unlike in
many other cells, as the vast amount of sarcomeric and DGC proteins within the fibers
push the nuclei below the outer cell membrane. This process is mediated by a com-
plex interaction of many proteins such as fibronectin, α-integrin, FAK and Src during
the maturing of the myoblasts (Roman et al., 2018) (Figure 1.7). Each nucleus within
the fiber expresses proteins to form the myofibrils, but only in a closely defined area,
which is consequently called nuclear domain (Ralston and Hall, 1989). These domains
are highly coordinated throughout the muscle and thus, all nuclei normally express the
same isoforms of MHC. However, muscle fibers in healthy people can also express
multiple isoforms of myosin heavy chains (Pette and Staron, 2000).
10
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Figure 1.7: Localization of multiple nuclei in skeletal muscle fibers.
(A) The schematic depiction of a skeletal muscle cross-section shows the form of skeletal muscle
fibers and the localization of myonuclei within the cells. (B) The picture shows the position of
multiple myonuclei under the sarcolemma on the outside of one single muscle fiber (Frontera
and Ochala, 2015; Allen et al., 1995).
1.2.5 Diversity of skeletal muscle fiber types
Skeletal muscle tissue has to satisfy many different demands, enabling the human body
to successfully navigate within their environment. These tasks include generating static
force for long periods, for example in trunk muscles, which straighten and stabilize the
spine, while standing upright. On the other hand, leg muscles have to be able to act
dynamically, as sprinting and jumping demand a high magnitude of force at once but
only for a very brief time. This means that muscle tissue has to conserve its energy
resources for long-lasting, low-intensity activity, but must also be able to increase the
energy output by a high margin almost instantaneously to successfully execute explo-
sive force needed in fight-and-flight situations. To better suit these diverse demands,
11
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evolution developed different muscle fiber types, which are adapted to exhibiting either
more static or dynamic activity.
Fiber types can be characterized by their biochemical attributes in terms of fatigue-
resistance, contraction time, mitochondria content, calcium release and reuptake by
the sarcoplasmic reticulum, predominance of metabolic pathways, ATPase activity and
extracellular properties such as the pericellular capillary density (Peter et al., 1972;
Lowry et al., 1978). These differences are not only attributes for the identification of
the fiber types, but reflect the adaptation during the evolutionary process (Buchthal and
Schmalbruch, 1980). In human skeletal muscles, there are three dominant fiber types
present, slow-twitching and fatigue resistant type I fibers, fast-twitching and moderately
fatigue resistant type IIa fibers and fast-twitching and fatigable type IIx fibers (Schiaffino
and Reggiani, 2011). Each muscle in the human body has slightly different tasks, as
muscles close to the trunk and those extending joints, especially in the lower limbs, are
particularly needed to maintain posture. Muscles more distant to the trunk, such as
forearm muscles, are generally rather utilized for fine motor skills, and thus rely to a
lesser extent on fatigue resistant fibers. It is therefore comprehensible that the propor-
tion of the different fiber types varies between muscles with almost exclusively postural
function and those used for precise and dynamic movement (Johnson et al., 1973).
Although muscle fibers can be characterized by the attributes mentioned above, the
identification is based on the different isoforms of myosin. In general, each muscle
fiber expresses only one specific isoform of myosin (Westerblad et al., 2010; Weiss
et al., 1999). Fiber types and their corresponding myosin heavy chains are listed in ta-
ble 1.1. Other histological and biochemical attributes, such as stronger capillarization,
glycogen content or the balance between oxidative and glycolytic metabolization are
substantiating factors to the function given by the myosin isoform (Pette and Staron,
2000).
Cross-sections of muscles reveal that the fibers of each type do not necessarily lie
directly next to each other but are distributed throughout the muscle in a checkerboard
like fashion (Figure 4.4) (Edström and Kugelberg, 1968). As motor neurons innervate
several ten to hundreds of muscle fibers and each of them are of the same fiber type, it
is obvious, that the territory taken up by the muscle fibers of one motor neuron overlaps
with the territory of others (Burke et al., 1974).
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Table 1.1: Overview of different fiber types and myosin isoforms.
Type I fiber Type IIa fiber Type IIx fiber
Myosin isoform MHC Iβ MHC IIa MHC IIx
Twitch speed slow fast fast
Twitch force low medium high
Fatigue resistance high high low
Glycogen content low high high
Capillary supply rich rich poor
Myoglobin high high low
Mitochondrial den-
sity
high high low
Alkaline ATPase ac-
tivity
low high high
Acidic ATPase ac-
tivity
high high low
Adapted and modified from (Peter et al., 1972; Pette and Staron, 2000).
Muscle fibers exhibit a limited potential of changing their biochemical properties, par-
ticularly the expression of different myosin isoforms, which renders the trans-differentiation
from one fiber type into another a high-energy process. This might occur under physi-
ological influences, such as a different pattern of excitation and by demanding a more
dynamic response, which can trigger a shift from slow- to fast-twitch fibers or a more
static response. Changes due to these influences can be observed in marathon run-
ners, who exhibit a larger amount of type I fibers or high jumpers, who exhibit many type
II fibers, respectively (Goldspink, 1998; Gutmann et al., 1972). Furthermore, hormone
blood levels, especially thyroid-stimulating hormone (TSH) (Ianuzzo et al., 1977), as
well as aging (Miller and Toth, 2013), contribute to an accentuated decrease in type II
fibers and to overall muscle atrophy. There is also evidence that hybrid fibers, express-
ing two or more different isoforms of myosin, occur more commonly in aging patients
than in younger adults (Andersen, 2003).
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Figure 1.8: Different fiber types and their distribution within muscle tissue.
The figure illustrates enzymatic activity of adenosinetriphosphatase (ATPase) in skeletal muscle
of humans. (A) Cross-sections of skeletal muscle of a young (left) and an old (right) person.
The young muscle depicts a checkerboard like distribution of fiber types whereas the old muscle
shows a distinct bundling of muscle fibers. ATPase staining (pH 4.6). (B) Both pictures show
ATPase stained longitudinal sections of a single skeletal muscle fiber of a person older than
85 years. In both cases a single muscle fiber exhibits more than one MHC type. The shift of
muscle fiber type can appear along the longitudinal axis (left) or originating from the domain
of a myonucleus (right). ATPase staining (pH 4.6). Dark fibers, type I fibers; white fibers, type
IIA fibers; grey fibers, type IIx (or I/IIa) fibers; scale bar = 100μm. Adapted and modified from
(Andersen, 2003).
1.3 Adaptation of skeletal muscle in aging
Aging is a complex process to which all organisms succumb, which affects many organs
including the musculoskeletal system. While skeletal muscle comprises up to 40% of
the body mass, changes in skeletal muscle are most likely to affect the mobility, espe-
cially of elderly people, to a great extent. In fact, various studies describe the loss of
skeletal muscle mass starting at the age of 40-50 years, with an increased loss from
60 years onwards and a loss of up to 50% of total skeletal muscle mass by the age
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of 80 years (Lexell et al., 1988; Booth et al., 1994; Lexell et al., 1986). Although the
loss of muscle mass is observable in all aging people, some people show a more rapid
progression of muscle loss. Additionally, the changes in muscle mass are shown to be
more obvious in males than in females (Yamada et al., 2014) (Figure 1.9).
Figure 1.9: Age-dependent loss of skeletal muscle mass.
The figure displays the relation of skeletal muscle mass of male and female humans to age.
Throughout the whole life females have less skeletal muscle mass than men, especially after
puberty the increase in muscle mass in males is accelerated. Loss of skeletal muscle mass
begins in midlife and is enhanced by the sedentary lifestyle of old people. Although females
generally depict less muscle mass, the loss during aging is less distinct in females compared to
males. Adapted by Smith and Mittendorfer (Smith and Mittendorfer, 2016).
This loss of muscle mass and function is also associated with lower mobility, result-
ing in a higher overall mortality (Kalyani et al., 2014; Dodds et al., 2015; Srikanthan
and Karlamangla, 2014) and is discussed to be a product of frailty, a syndrome char-
acterized by the reduction of musculoskeletal function, aerobic capacity, cognitive and
integrative function and nutritional reserves (Campbell and Buchner, 1997). Hence, an
overall reduced capability in life-sustaining body functions, which leads to higher risks
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of chronic diseases, complicated courses of disease and a hindered ability to overcome
traumas and hospitalization (Muscedere et al., 2017). The interaction between skeletal
muscle loss, physical impairment, chronic disease and frailty has already been hypoth-
esized as a cycle with a reciprocal sustentation ultimately leading to death (Aguirre and
Villareal, 2015). The causes for this cycle however have not yet been fully uncovered
and might considerably differ between individuals.
During aging, skeletal muscle tissue also depicts very distinct changes. Although the
loss of muscle mass is generally accelerated, lower limb muscles show an accentuated
weight loss compared to upper limbs muscles (Lynch et al., 1999), which demonstrates
a non-uniform muscle adaptation throughout the whole body. The reasons for the loss
of muscle mass and a decrease in physical performance include the atrophy of muscle
fibers and the increase of connective and fat tissue between the fibers (Fielding et al.,
2011). In addition, muscle fibers are shown to be affected by atrophy depending on
their fiber type. In vastus lateralis and gastrocnemius muscle, the atrophy and eventual
loss of fast-twitching type II muscle fibers was shown to be more prevalent than in the
slower acting type I fibers (Tellis et al., 2011; Coggan et al., 1992). This leads to a higher
proportion of fatigue resistant type I fibers within the skeletal muscle and thus to a better
conservation of energy, which might be beneficial for older people, who exhibit lower
reserve capacities than younger adults. The reduced number of motor neurons inner-
vating skeletal muscles contributes to the transition from fast-twitching skeletal muscle
fibers to slow-twitching fibers. Motor neurons in the spinal cord degenerate with aging
and thus decline in numbers, resulting in an accumulation of denervated muscle fibers
(Aare et al., 2016; Rowan et al., 2012). The residing motor neurons adapt to this atrophy
by re-innervating denervated muscle fibers to a limited extend, potentially forcing the
reinnervated fibers to change their fiber type, developing large groups of muscle fibers
of the same fiber type (Doherty et al., 1993; Kanda and Hashizume, 1989; Tudoraşcu
et al., 2014).
In addition, within skeletal muscles, the number of satellite cells reduces during aging,
especially around type II fibers, which might contribute to the ongoing loss of such mus-
cle fibers (Verdijk et al., 2007). The performance of single muscle fibers themselves is
also impaired, as it is shown that cell organelles and contractile proteins degenerate
over time. Muscle fibers of old humans contain significantly less actin and myosin com-
pared to muscle fibers of younger patients (Miller and Toth, 2013). Thus, the force
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generated and the elasticity of a single muscle fibers is lower in elderly than in young
adults (Ochala et al., 2007). This relation of force generation and elasticity is thought
to be an adaptive mechanism to reduce the energy needed for efficient day-to-day ac-
tivities. Increasing stiffness could thereby compensate less efficient muscle contraction
and sustain motoric stability. The sarcoplasmic reticulum is noticeably reduced in its
capacity to hold calcium homeostasis due to an increasing number of segregated com-
partments, which hold calcium that cannot be mobilized and is thus separated from
the excitation-contraction mechanism (Weisleder et al., 2006). Beside the changes of
calcium homeostasis within the sarcoplasmic reticulum, also mitochondrial function is
affected during aging. Although it is not yet clear if the loss of fibers is due to a de-
creased number of mitochondria or vice versa, it has been shown that age alone is
not solely responsible for a lesser density of mitochondria. Elderly people often tend
to a more sedentary lifestyle, but are generally able to regain mitochondrial function
with sufficient exercise (Broskey et al., 2014; Cadore and Izquierdo, 2013). However,
mitochondrial function might also be compromised by accumulated mutations in mito-
chondrial DNA, when mutated mitochondria reach a critical threshold in muscle fibers
(Wang et al., 2001). This observation is underlined by the fact that induced mutations in
mitochondrial DNA lead to a significantly increased loss of muscle fibers (Herbst et al.,
2016). Furthermore, mitochondria produce reactive oxygen species (ROS) that can
harm the content of the cell by uncontrolled oxidation of cell structures. The generation
of ROS is increased with aging and the oxidative stress affects proteins of the contractile
apparatus. Especially for the binding sites of actin and myosin it is shown, that oxida-
tive stress can impair muscle function by decreasing the gene expression and therein
lowers the content of contractile protein and by modifying amino acid side chains, which
leads to an impaired ability to produce force (Moen et al., 2014).
This underlines that not only loss of muscle mass itself leads to the impaired physical
ability of the elderly human, but also a wide range of effects, caused by aging, result in
the functional loss of skeletal muscle, although their relative contribution is not yet fully
resolved.
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1.4 Sarcopenia: a pathologic form of aging?
For many decades, aging has been known to be associated with a generalized atrophy
of several organ systems. Especially the loss of appendicular lean body mass, and
therewith fading strength, are perceptible changes that occur in all humans. The in-
creasing loss of skeletal muscle mass in aging adults has long had no specific name,
although it has been of interest at least since the early twentieth century. With intensi-
fied focus on the aging society the term sarcopenia first occurred in an article by Irwin
Rosenberg in 1987 (Rosenberg, 1989). The term sarcopenia was derived from the
greek word ‘sarx’ for flesh and ‘penia’ for loss and was used to describe changes in
body composition and their related functions in the context of aging. The subsequently
defined syndrome sarcopenia featured the age-related loss of muscle mass, which was
believed to be a predictor of impaired physical performance and therefore waning inde-
pendence of people in old age. Looking solely on muscle mass, at what point does a
human experience constraint in fitness?
By looking at world-class athletes in various fields, it is peculiar how each individual
adapts to different physical tasks and excels peak performances. It is therefore de-
ducible that strength, and hence physical performance, does not necessarily depend
solely on sheer skeletal muscle mass. Indeed, it has been shown that not muscle mass
but muscle strength is independently associated with physical performance (Visser
et al., 2000). Consequently, if in young humans, as well as aging humans, skeletal mus-
cle mass is not the only crucial factor that determines fitness, skeletal muscle strength
could be a relevant determinant of independence (Dodds et al., 2015). In fact, mus-
cle strength and physical function are directly associated with higher rates of disability
and mortality (Cesari et al., 2009). This was demonstrated by the fact that neither
muscle mass in calf muscles nor fat mass are significantly relevant risk factors for mor-
tality, but that strength measured in quadriceps as well as grip strength provide equally
sensitive markers to determine the mortality risk (Manini et al., 2007; Newman et al.,
2006). These findings are crucial information to broaden the picture of sarcopenia, and
thus, a revised definition was created by the European Working Group on Sarcopenia
(EWGSOP) in 2011 that describes sarcopenia as a syndrome consisting of low skele-
tal muscle mass and additionally either low muscle strength, physical performance or
both (Cruz-Jentoft et al., 2010). The definition of sarcopenia by the EWGSOP has been
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proven as a valid predictor of poor health outcomes (Landi et al., 2012b). As the body
composition changes and muscle strength declines with age, although individually dif-
ferent, it is an inevitable process found throughout all humans. This raises the question,
if sarcopenia can be considered a form of physiological aging, a disability or a disease.
To address this question properly, it is important to elucidate the causes of sarcopenia.
Sarcopenia is a medical state, mediated by a complex multifactorial pathophysiology
with various differently weighted factors contributing to the loss of muscle mass and
strength. There are major mechanisms considered to be involved in the genesis, which
include the physical activity, neuromuscular integrity, protein metabolism, regulation of
gene expression, endocrine milieu, circulating pro-inflammatory mediators and apopto-
sis. A sedentary lifestyle is the main factor that contributes to muscle weakness and this
again promotes a further emphasized loss of strength itself (Aguirre and Villareal, 2015;
Groessl et al., 2019). In contrast, physical exercise represents an important counter-
measure to prevent weakness (Marzetti et al., 2017). Resistance training influences
muscle mass and strength, mainly by the increase of the size and number of myofibrils,
whereas type II muscle fibers are predominantly involved (Suetta et al., 2008). While
this effect is observable in exercising muscles and represents a major benefit for older
people, it is obvious how the absence of physical exercise can negatively affect skeletal
muscle function and can therefore be considered a primary risk factor for the develop-
ment of physical disabilities (Steffl et al., 2017).
Furthermore, skeletal muscle protein translation is also dependent on the proteinmetabolism.
Imbalances in the synthesis and degradation in favor of degradation tends to weaken the
contractile elements of skeletal muscle fibers. There are various causes for imbalances
in protein turnover, with a driving reason being non-sufficient intake of metabolites, es-
pecially amino acids (Pasini et al., 2018). It has been demonstrated that in addition to
resistance training, a supplementation of amino acids, mainly leucine, represent impor-
tant anabolic stimuli in skeletal muscle protein synthesis (Makanae and Fujita, 2015).
Both a leucine enriched nutrition supplementation and resistance training induce protein
synthesis by activating mammalian target of rapamycin (mTOR) and ribosomal protein
S6 kinase (S6K1) pathways (Anthony et al., 2001; Ogasawara et al., 2014). A lack of
resistance exercise or appropriate nutrient intake negatively affects muscle hypertrophy
and thus strength. Indeed, meta-analyses that evaluated the association of low protein
intake with physical function could show that a high protein intake of >1.0 g/kg/d was
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correlated to higher lower limb strength (Coelho-Júnior et al., 2018).
As skeletal muscle fibers do not act independently, it is evident that the motor neurons
in the spinal cord must play a key role in the physiological function and maintenance
of skeletal muscle. Analogous to known neurodegenerative diseases such as amy-
otrophic lateral sclerosis (ALS), the loss of motor neurons in both ALS and aging is a
further risk factor in the development of weakness and disability. The atrophy of neurons
responsible for the activation of muscle fibers leads to weakness and further atrophy
of the given muscle. Pathophysiological causes are theorized to be “dying-back” and
“transsynaptic degeneration” mechanisms, pathological changes in axons prior to neu-
ron degeneration, which are also found in humans depicting sarcopenia, but to a lesser
extent respectively (Fischer et al., 2004; Tintignac et al., 2015). Although the decline in
motor neuron number with increasing age does not have the same impact as neurode-
generative diseases, it has nevertheless been shown that it is significantly associated
with the occurrence of sarcopenia and could help as a role model in studying the influ-
ence of neuromuscular integrity in sarcopenic patients (Drey et al., 2014; Rowan et al.,
2012; Pannérec et al., 2016).
Skeletal muscle structure, metabolism and neuromuscular function as well do all stand,
to some extent, in the context of the endocrine milieu and circulating inflammatory medi-
ators. Both skeletal muscle mass and strength are known to be negatively influenced by
chronic diseases and inflammation (Bano et al., 2017). In addition to that, several stud-
ies have demonstrated that imbalances in the endocrine milieu as they occur in several
diseases, have a negative effect on skeletal muscle. Glucocorticoids feature metabolic
effects, among other things shifting protein turnover towards catabolic states. Signif-
icantly higher excretion of glucocorticoids in patients with Cushing’s syndrome there-
fore lead to higher protein degradation and consequently to significantly less muscle
strength (Berr et al., 2017). Vitamin D has been demonstrated to exerpt a positive ef-
fect on the growth of skeletal muscle (Wagatsuma and Sakuma, 2014). Although the
exact molecular effects have not yet been fully understood, it is possible to assume, that
a lack of vitamin D might be one influential factor on sarcopenia. Likewise, it could be
demonstrated, that a supplementation in vitamin D has a positive effect in the treatment
of sarcopenic patients (Bauer et al., 2015; Tessier and Chevalier, 2018). Furthermore,
chronic inflammation affects skeletal muscle tissue negatively. Increased expression of
tumor necrosis factor α (TNF-α) stimulates ubiquitin-dependent ligases E1, E2 and E3,
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which increase protein degradation (Jo et al., 2012; Patel and Patel, 2017).
Although sarcopenia as a syndrome is contoured clearly, the complexity of the multifac-
torial cause underlines the quandary of clinical practice. Identifying patients with a clear
cause might prove to be difficult if not impossible, given the fact that the various factors
determining loss of muscle mass and strength weighing differently from individual to
individual or might even be absent at all. It is therefore important to further investigate
causes for sarcopenia that are generally present and to differentiate them from those
which are specific to certain diseases that promote sarcopenia themselves.
1.5 Prevalence and socio-economic significance
The question whether sarcopenia is a form of aging, a disability or a disease has not
yet been fully elucidated, yet the consequences of weakness in old age, with no doubt,
cannot be denied. Beside the difficulties in clinical practice, such as defining and diag-
nosing sarcopenia efficiently, it is important to understand the impact of sarcopenia on
the society. Clearly defining a syndrome and attribute diagnostic parameters for com-
parability are needed to consistently survey large cohorts in a society.
Using the definition provided by the EWGSOP, several studies have estimated num-
bers of people deemed to be sarcopenic. A systematic review by Cruz-Jentoft et al.
examined multiple prevalence studies on sarcopenia in western countries and revealed
a share of 1 to 29% of community-dwelling people, 14 to 33% of elderly in long-term
housing and 10% of patients in acute hospital-care to be sarcopenic (Cruz-Jentoft et al.,
2014). The German FORMoSA study found 4.5% of 1,325 community-dwelling female
participants aged 70 years and above to be sarcopenic (Kemmler et al., 2015), a rela-
tively low amount. However, participants in the study with osteoarthritis were found to
be at a higher risk for sarcopenia. Prevalence in Japan has been shown to be 21.8%
for men and 22.1% for women in community-dwelling elderly aged 65 to 89 years (Ya-
mada et al., 2013). Different studies also focused of special cohorts, which are thought
to exhibit risk factors for poor health outcomes. In the group of people aged 80 years
and above, the BEFRAIL study, conducted in Belgium, classified 12.5% of the 567 par-
ticipants as sarcopenic (Legrand et al., 2013). The Newcastle 85+ study investigated
the prevalence of people aged 85 and above in the UK and came to a share of 21% of
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the 845 participants (Dodds et al., 2017). Additionally, 32.8% of elderly over 70 years
living in nursing homes were sarcopenic (Landi et al., 2012a). Furthermore, multivari-
ate analysis depicted a higher risk for sarcopenia in male nursing home residents and
in those with cerebrovascular disease and/or osteoarthritis. Sarcopenia was less likely
in those residents involved in regular physical activity, underlining the importance of ex-
ercise, even in old age. These studies also suggest that the prevalence of sarcopenia
increases with increasing age.
The importance of sarcopenia cannot be deduced by the high prevalence in aging peo-
ple alone. In fact, sarcopenia has been shown to be associated with significantly poorer
health outcomes compared to non-sarcopenic people. Ameta-analysis to review short-,
middle- and long-term outcomes of sarcopenia came to the result that sarcopenia signif-
icantly affects mortality negatively (Beaudart et al., 2017). In addition, a higher fall rate
and a higher incidence of hospitalization were reported. In nursing homes, residents
with sarcopenia were 2.34 times more likely to die (Landi et al., 2012b). Additionally, in
South Korea the risk for death in sarcopenic people was assessed to be between 2.99
and 3.22 times higher than in non-sarcopenic people (Kim et al., 2014).
The prevalence of sarcopenia in people of old age is relatively high and with sarcopenia
being a major risk factor, the economic burden is conspicuous. Furthermore, the share
of people aged 80 yeas and higher is the fastest growing group worldwide (United Na-
tions and Social Affairs, 2017) This means, that not only the aging of the population
itself, but also the associated risks for poor health represent a major economic burden
that will continue to grow in the future (Bloom et al., 2015).
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Aim of the study
It has been shown that with increasing age, humans lose muscle mass and are increas-
ingly impaired in physical performance, which diminishes their ability to participate in
activities of day-to-day living. With reduced fitness health risks such as falls, hospital-
ization rates are also increasing. Furthermore, sarcopenia represents a health issue of
increasing economic burden, which will further grow with the demographic change of
the population. It is therefore obvious that musculoskeletal function is of high interest
and containing strength is necessary for managing health demands of elderly patients.
Current recommendations for treatment of sarcopenia contain supplementation of vi-
tamin D and proteins (Bauer et al., 2015; Malafarina et al., 2013), as well as strength
training and conditioning (Cadore and Izquierdo, 2013; Theou et al., 2011). However,
especially training is often difficult for old adults, which makes a specific pharmacolog-
ical therapy highly valuable.
For the challenge of finding new possible treatments for sarcopenia, we must clarify the
impact of the different causes that lead to sarcopenia. Physiological, as well as patho-
logical influences, such as weight-load, innervation and hormone levels can change the
relative proportion of fiber types in the skeletal muscle (Izumo et al., 1986; Pette et al.,
2002). To this date, it has been investigated that human skeletal muscle undergoes
change during aging. However, morphological differences between skeletal muscle of
sarcopenic and non-sarcopenic humans have not been described. For this purpose, we
took samples of gluteus medius muscle from patients with proximal hip fractures, who
underwent surgery at the Department of General, Trauma and Reconstructive Surgery
at the University Hospital of Munich. We assessed skeletal muscle mass via bioelectri-
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cal impedance analysis (BIA), measured handgrip strength with a hand dynamometer
and analyzed blood levels of thyroid-stimulating hormone (TSH), 25-hydroxyvitamin D
(25(OH)D), total protein and calcium. Furthermore, we hypothesized that patients with
a higher skeletal muscle index depict generally bigger muscle fibers, especially of type
IIa and IIx fibers and a higher proportion of fast-twitching fibers compared to patients
with lower skeletal muscle index.
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Materials & Methods
3.1 Ethics statement and sample acquisition
This study was approved by the ethics committee of the Ludwig-Maximilians-University
Munich (265-16) and declares itself to adhere to ethical standards and the generally
accepted rules of medicine. Between 08/2016 and 03/2017, 20 patients with proximal
femoral fractures were included in this study after signing an informed consent. Patients
with acute or chronic infections, psychiatric or neurologic diseases, cancer, pregnancy,
infections with human immunodeficiency virus (HIV), hepatitis B (HBV) and C (HCV)
were excluded. All biopsies were collected by a trained surgeon under adherence to all
current surgical standards during operation.
3.2 Clinical assessment and bioelectrical impedance
analysis
The patients’ mobility and activities of daily living prior to the fracture were assessed with
a questionnaire including the Barthel index (Mahoney and Barthel, 1965), the Parker
mobility score (Parker and Palmer, 1993) and the SARC-F score (Malmstrom et al.,
2016). Each of those contain questions about the ability to conduct daily activities in-
dependently, such as walking, climbing stairs, getting up from chairs, dressing, using
the toilet, etc. (for detailed view, the questionnaires used in this study are appended
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in the supplementary data). The maximum handgrip strength was determined by a
dynamometer (DynExTM, Akern, Italy). Three measurements on each side were per-
formed and the highest value was selected. Additionally, the skeletal muscle mass was
approximated using a bioelectrical impedance analysis (BIA). Patients had to be lying
straight for at least five minutes before the examination was performed with a BIA de-
vice (BIA 101 Anniversary, SMT medical GmbH & CO. KG, Germany). The BIA was
conducted bipolar with two electrodes on either the left or right hand and foot, regarding
the absence of implants on that side of the body, avoiding contact between the extrem-
ities. The resistance value was then used to determine the total skeletal muscle mass
and the skeletal muscle index (SMI) using the Janssen equation
SMM =
(
Ht2 ∗ 0.401
R
)
+ (gender ∗ 3.825) + (age ∗ −0.071) + 5.102
where SMM = skeletal muscle mass [kg], Ht = height [cm], R = resistance [Ω], gender
= 0 for female or 1 for male and age = patient’s age [years] (Janssen et al., 2000). The
SMI was then calculated by dividing the total skeletal muscle mass by the height in me-
ters squared.
3.3 Collection and processing of skeletal muscle
biopsies
Biopsies of the gluteus medius muscle were obtained during surgical treatment of the
proximal femur fractures either by cephalomedullary nailing or hip arthroplasty. No
longer than ten minutes after acquisition the collected samples were immersed in Tis-
sueTek O.C.T. (Sakura Finetek, Japan) and immediately frozen in liquid nitrogen cooled
isopentane (Sigma-Aldrich, USA). Biopsies were then cut into 10 μm thick sections with
a cryotome (ThermoFisher Scientific, USA) and stored at -80◦C until further usage.
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3.4 Immunohistochemistry
Sections were thawed at room temperature, fixed in acetone (Sigma-Aldrich, USA) for
10 minutes, rehydrated with PBS-T (phosphate-buffered saline with 0.1% Triton) (Sigma
Aldrich, USA) and blocked in heat-inactivated horse serum (10% in PBS, ThermoFisher
Scientific, USA) at room temperature for one hour. Afterwards, sections were incubated
at 4◦C overnight with primary antibodies against myosin heavy chain (MHC) type 7 (BA-
F8, 1:25), MHC type 1 (6H1, 1:25, all MHC antibodies were obtained from the Devel-
opmental Studies Hybridoma Bank developed under the auspices of the NICHD and
maintained by The University of Iowa, Department of Biological Sciences, Iowa City,
IA 52242) and Laminin 1 (ab11575, 1:200, Abcam, UK). The sections were washed
in PBS-T three times for 5 minutes at room temperature and incubated at room tem-
perature for one hour with appropriate fluorochrome-conjugated secondary antibodies
(1:250, ThermoFisher Scientific, USA). Finally, sections were washed in PBS, coun-
terstained with 3,3’ diaminobenzidine (DAPI), rinsed in PBS and mounted with Fluoro-
mount (Sigma-Aldrich, USA).
3.5 Cytochrome C oxidase/succinate dehydrogenase
(COX/SDH) histochemistry
The double-labeling method reveals both cytochrome c oxidase and succinate dehydro-
genase function. Cells with functioning cytochrome c oxidase enrich brown indamine
polymer product, while cells with defect mtDNA are not saturated by indamine polymer
but succinate dehydrogenase reduces nitro blue tetrazolium (NBT) to blue formazan.
Thus, COX/SDH staining reveals cells without defects in mtDNA, or negative cells, as
brown and cells with altered mtDNA, or positive cells, as blue.
Consecutive slides of the immunohistochemical staining were thawed at room temper-
ature and placed in an incubation medium containing 3,3’-diaminobenzidine, bovine
catalase, cytochrome c oxidase, sucrose (all from Sigma-Aldrich, USA) in PBS at room
temperature for two hours. Afterwards, the sections were rinsed in distilled water and
placed in a counterstaining medium containing NBT (Sigma-Aldrich, USA) and sodium
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succinate (Sigma-Aldrich, USA) in a sodium dihydrogen phosphate and disodium hy-
drogen phosphate solution (Sigma-Aldrich, USA) at 37◦C for two hours. The slides
were then rinsed in water, dehydrated ethanol, cleared in xylene and then mounted us-
ing Roti-Mount (Carl Roth GmbH + Co. KG, Germany).
3.6 Image analysis
All pictures of the whole biopsy cross sections were taken via fluorescence microscopy
(AxioObserver Z1, Zeiss). Fibers were counted and their area measured using Fiji (Im-
ageJ, National Institute of Health, USA).
3.7 Statistical analysis
The collected data was evaluated for statistical significancewith GraphPadPrism (USA).
For statistical analysis a t-test for parametric data was performed, respectively a Mann-
Whitney-U-test for non-parametric data. A p-value ≤ 0.05 was considered significant.
For correlation analysis, the Spearman’s rank correlation coefficient was calculated.
Group data are represented by the mean and the standard deviation (SD). Correlation
are represented by mean and confidence interval (CI) of 95%.
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Table 3.1: Instruments & chemicals.
Instruments
DynExTM dynamometer Akern, Italy
BIA 101 Anniversary SMT medical GmbH & CO. KG, Germany
CryoStarTM NX50 Cryostat Thermo Fisher Scientific Inc., USA
AxioObserver Z1 Zeiss, Germany
Antibodies & Chemicals
TissueTek O.C.T. Sakura Finetek, Japan
BA-F8, against MHC type 7 DSHB, USA
6H1, against MHC type 1 DSHB, USA
ab11575, against laminin 1 Abcam, UK
DAPI (4’,6-diamidino-2-phenylindole) Thermo Fisher Scientific Inc., USA
FluoromountTM Sigma-Aldrich, USA
DAB (3,3’-diaminobenzidine) Sigma-Aldrich, USA
bovine catalase Sigma-Aldrich, USA
cytochrome c oxidase Sigma-Aldrich, USA
sucrose Sigma-Aldrich, USA
NBT (nitro blue tetrazolium) Sigma-Aldrich, USA
sodium succinate Sigma-Aldrich, USA
sodium dihydrogen phosphate Sigma-Aldrich, USA
disodium hydrogen phosphate Sigma-Aldrich, USA
Roti-MountTM Carl Roth GmbH & Co. KG, Germany
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Results
4.1 Patient collective
We included a total of 20 patients from the Department of General, Trauma and Re-
constructive Surgery at the Munich University Hospital, LMU into our study. Of those,
15 were female and 5 were male. The average age of all individuals was 79.6 ± 10.4
years, with a mean age of female patients of 82.7 ± 7.1 years and a mean age of male
patients of 70.2 ± 12.7 years.
All individuals were measured for their skeletal muscle mass (SMM), their body mass
index (BMI) and their skeletal muscle index (SMI). The average SMM in the study group
was 23.3 ± 6.2 kg, the average BMI was 23.2 ± 4.1 kg/m2 and the average SMI was
8.2 ± 1.5 kg/m2. The female patients’ SMM was 20.5 ± 4.5 kg, the BMI was 23.2 ± 3.9
kg/m2 and the SMI was 7.7 ± 1.4 kg/m2, whereas the males’ SMM was 31.4 ± 2.6 kg,
the BMI was 23.3 ± 4.5 kg/m2 and the SMI was 9.6 ± 0.6 kg/m2.
We also compared the SMM, BMI and SMI of the female patients with the male patients
and could show that both the SMM and the SMI of males were significantly higher than
in women (Figure 4.1, A p ≤ 0.01; C p ≤ 0.01), but the BMI did not differ between the
two groups (Figure 4.1, C p = 0.96), hence showing that the men had a higher propor-
tion of skeletal muscle than the women (Table 7.1).
As one criterion for diagnosing sarcopenia is muscle function, we had to utilize a
surrogate test to evaluate the fitness of our participants prior to the hip fracture. For
this, the physical performance was estimated by the utilization of the clinical scores:
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Figure 4.1: Comparison of skeletal muscle mass, body mass index and skeletal muscle
index in the patient collective.
The graphs show the individual data of the overall study group and divided into female and
male patients, plotted for skeletal muscle mass, body mass index and skeletal muscle index.
The skeletal muscle mass of men was significantly higher compared to women (A p ≤ 0.01). In
contrast, there was no difference of the body mass index between men and women (B p = 0.96),
with the skeletal muscle index of men also being significantly higher than the skeletal muscle
index of women (C p ≤ 0.01). f: female, m: male. Data points represent individual donors.
Error bars represent the mean ± SD. * equals p ≤ 0.05.
Barthel index, parker mobility score and SARC-F score. In addition, handgrip strength
was measured in all patients using a handgrip dynamometer.
On average, the study group conducted 20.9± 10.6 kg weight force with their dominant
hand. Additionally, they scored 94.4 ± 7.2 points in the Barthel index, 7.1 ± 1.7 points
in the parker mobility score and 3.4 ± 2.4 points in the SARC-F score. The female pa-
tients conducted 16.7 ± 5.6 kg weight force and scored 94.3 ± 7.2 points in the Barthel
index, 6.9 ± 1.7 points in the parker mobility score and 3.6 ± 2.2 points in the SARC-F
score, whereas the male patients conducted 33.7 ± 11.6 kg weight force and scored
95.0 ± 7.1 points in the Barthel index, 8.0 ± 1.4 points in the parker mobility score and
2.3 ± 2.6 points in the SARC-F score. By comparing the female and male participants
in regard to the values of the physical performance questionnaires, we could show no
significant difference between men and women (Figure 4.2, A p = 0.73; B p = 0.38;
C p = 0.57). Thus, we could say that men in our study group did not generally state
higher values in the physical performance questionnaires, despite higher skeletal mus-
cle mass and handgrip strength.
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Figure 4.2: Physical performance values of the patient collective.
The graphs show the individual data of the overall study group and divided into female and
male patients, plotted for Barthel index, parker mobility score and SARC F score. Between men
and women we could not find any significant differences in regard to physical impairment, as
the Barthel index scores, the parker mobility score values and SARC F score values do not
significantly differ(A p = 0.73; B p = 0.38; C p = 0.57). f: female, m: male. Data points represent
individual donors. Error bars represent the mean ± SD.
In sarcopenia, endocrine function and osteoporosis are known confounding vari-
ables that might influence the onset of muscle loss. Hence, we took blood samples from
the study participants and quantified serum levels of 25(OH)D, TSH, total protein and
calcium to evaluate disrupting factors, as particularly low thyroid function, osteoporosis
and malnutrition might not yet have been diagnosed in our patients. In all individuals
combined, the average level of 25(OH)D was 16.0 ± 11.5 ng/ml, TSH was 1.35 ± 0.69
μU/ml, total protein was 5.4 ± 0.5 g/dl and of calcium was 2.05 ± 0.1 mmol/l. The
average serum level measured in all female participants of 25(OH)D was 17.3 ± 12.8
ng/ml, TSH was 1.39 ± 0.73 μU/ml, total protein was 5.3 ± 0.5 g/dl and calcium was
2.05 ± 0.11 mmol/l, whereas for males the mean serum level of 25(OH)D was 11.6 ±
2.9 ng/ml, TSH was 1.24± 0.57 μU/ml, total protein was 5.7± 0.3 g/dl and calcium was
2.05 ± 0.05 mmol/l. Furthermore, we compared the blood levels of all the parameters
mentioned above in the female participants with the blood levels of the male partici-
pants and could find no significant difference between these two groups (Figure 4.3,
A p = 0.18; B p = 0.69; C p = 0.09; D p = 0.99). Although female and male adults did
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not show differing blood levels of 25(OH)D, a striking fact is that aside from one female
patient, all other study participants did show a lack of 25(OH)D.
Figure 4.3: Blood levels of 25(OH)D, TSH, total protein and calcium in the patient collec-
tive.
The graphs show the individual data of the overall study group and divided into female and male
patients, plotted for 25(OH)D, TSH, total protein and calcium. The comparison of the blood levels
showed no significant difference in neither 25(OH)D (A p = 0.18), TSH (B p = 0.69), total protein
(C p = 0.09) nor calcium (D p = 0.99) between men and women. f: female, m: male. Data points
represent individual donors. Error bars represent the mean ± SD.
4.2 Morphological analysis of cross-sections from glu-
teus medius muscle
From each patient in our study, we collected a muscle biopsy of the gluteus medius
muscle during the operation of their proximal femoral fracture. We cut the biopsies
into cross-sections and stained them according to our protocol for slow twitching type
I fibers and fast twitching type IIx fibers, leaving the type IIa fibers unstained and thus
appearing black in fluorescence microscopy. Hence, we were able to count all fibers of
each fiber type present in all biopsies and measure their size.
On average, each biopsy contained 3,040 ± 1,779 fibers, which was vastly dependent
on the overall size of the biopsy. Each fiber had an average size of 3,385 ± 952 μm2.
The mean fiber area of each fiber type was measured individually, which revealed, that
type I fibers had an average fiber size of 5,885± 2,363 μm2, while type IIa fibers had an
average fiber size of 2,996 ± 1,523 μm2 and type IIx fibers of 2,232 ± 1,041 μm2. This
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showed, that type I fibers were significantly bigger than type IIa (p ≤ 0.01) and type IIx
fibers (p ≤ 0.01). The average size of muscle fibers in females was 5,832 ± 2,438 μm2
for type I, 2,282 ± 1,375 μm2 type IIa and 1,522 ± 879 μm2 for type IIx respectively.
In male participants, muscle fibers were 4,803 ± 1,928 μm2 for type I, 2,980 ± 1,707
μm2 for type IIa and 2,020 ± 1,474 μm2 for type IIx. Additionally, we analyzed the fiber
type proportion within the biopsies and could show that type I fibers were significantly
dominant in all biopsies with a proportion of 79.14± 16.50% (p≤ 0.01). In contrast, the
proportion of type IIa fibers was 11.84± 9.64% and the share of type IIx fibers was 9.02
± 8.98%. In females the share of type I fibers with 81.41 ± 15.47% was higher than in
men with 72.24± 17.5%, whereas type IIa and type IIx fibers were less dominant. Type
IIa fibers held a share of 11.06 ± 9.3% in female and 14.36 ± 10.06% in male. Type
IIx fibers were less common with 7.5 ± 7.9% in females and 13.4 ± 10.4% in males.
Noticeably, while analyzing the cross-sections, we discovered that 10 out of 20 biop-
sies depicted fiber bundling of type I fibers (Figure 4.4). In all these cases several fiber
bundles contained only type I fibers. This ranged from several bundles without type IIa
and IIx fibers to biopsies completely without type IIx fibers and almost no type IIa fibers,
which was the case for four biopsies. We could see in one biopsy the lack of both type
IIa and IIx fibers.
4.3 Handgrip strength declines with age
We analyzed handgrip strength of the dominant hand with a dynamometer in all pa-
tients and compared the achieved weight force to age and SMI. We found that hand-
grip strength declines with aging (p ≤ 0.05, R2 = 0.57). Also, by comparing handgrip
strength to SMI, we found that strength correlated to skeletal muscle mass (p≤ 0.05, R2
= 0.51). These results were expected and are concordant to existing literature (Visser
et al., 2000). The corresponding figures are appended in the supplementary data (Fig-
ure 7.1).
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Figure 4.4: Skeletal muscle biopsy cross-sections of six individuals.
The figure depicts the immunohistochemical staining of skeletal muscle cross-sections of six in-
dividual participants in the study. MHC7 (type I; green), MHC1 (type IIx; red), laminin 1 (white),
DAPI (blue). Type IIa fibers are not stained and appear black (white arrow head). Type I fibers
are dominant in all six participants, whereas type IIa and type IIx fibers are less common. Ad-
ditionally, the proportion of fast twitching fibers was highly variant. Fast-twitching fibers were
generally smaller and appeared “flattened” more often compared to type I fibers. Several cross-
sections depicted pronounced bundling of type I fibers with few to no type II fibers in fiber bun-
dles. Scale bar: 200 μm.
4.4 Prevalence of sarcopenia does not correlate to
mitochondrial dysfunction
In addition to immunohistochemical staining, we also stained gluteus medius cross-
sections for mitochondrial dysfunction with cytochrome c oxidase/succinate dehydro-
genase histochemistry (Ross, 2011). We analyzed gluteus medius cross-sections of
all participants via COX/SDH staining and found out, that the amount of blue positive
fibers was extremely low. In fact, there were few to none positive cells in each of the
participants (Figure 7.2).
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4.5 Themean fiber area of fast-twitching fibers declines
with aging
As muscle mass in aging adults decreases from about 30 years onwards with an ac-
celerated loss from the age of 60 onwards (Lexell et al., 1986), we correlated the loss
of muscle mass to either the loss of muscle fibers in number and to the loss in size of
each individual fiber. We compared the mean fiber area of each fiber type to the age
of the corresponding individual. The analysis revealed that the mean fiber area of type
I fibers does not correlate to age (A p = 0.96, R2 ≤ 0.01). However, type IIa and type
IIx fiber size decreases with aging (B p ≤ 0.01, R2 = 0.38, respectively C p ≤ 0.01,
R2 = 0.65). A noticeable feature is the variance of the mean fiber area between the
individuals, most obvious in type I fibers, but also in type IIa and type IIx fibers (Figure
4.5, A-C). Furthermore, the percentage of fiber types in the biopsies varies strongly
from individual to individual, as the share of type I fibers ranges from 50% to 100% (on
average 79.1%± 16.5%). Type IIa fiber proportion ranges from 0% to 30% (on average
11.9% ± 9.6%) and type IIx fiber share ranges from 0% to 30% (on average 9.0% ±
9.0%). With higher age, the distribution does not change to the favor of one fiber type
but varies randomly depending on each individual (Figure 4.5, D type I: p = 0.96, R2 ≤
0.01; type IIa: p = 0.87, R2 ≤ 0.01; type IIx: p = 0.78, R2 ≤ 0.01).
4.6 The mean fiber area does not correlate to skeletal
muscle index
Sarcopenia is defined by the EWGSOP as a loss of muscle mass and additionally, a
loss of muscle strength and/or physical performance (Cruz-Jentoft et al., 2010), where
the muscle mass is determined through calculating the skeletal muscle index (SMI) of
each individual with the Janssen equation (Janssen et al., 2000). Thus, we evaluated,
if individuals with lower skeletal muscle mass showed any differences in fiber type size
or distribution within their muscles. We therefore compared the mean fiber size to the
SMI of any individual and we could show that the mean fiber area of each fiber type
does not correlate to the measured SMI (Figure 4.6, A p = 0.54, R2 ≤ 0.02; B p = 0.5,
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Figure 4.5: Change of mean fiber area during aging and fiber type proportion compared
to age.
Fibers of each type weremeasured in size and the average was compared to the age of the given
individual (A-C). Each patient’s fiber type distribution is displayed as a bar of corresponding color
(D fiber type I: green; type IIa: black; type IIx: red). While the mean fiber CSA of type I fibers
shows no significant change during aging (A p = 0.96, R2 ≤ 0.01), the CSA of type IIa (B) and
type IIx (C) fibers revealed a significant decline in aged patients (B p ≤ 0.01, R2 = 0.38; C p ≤
0.01, R2 = 0.65). Quantification of the fiber type proportion of the gluteus medius muscle does
not show any obvious correlation with aging (D type I: p = 0.96, R2 ≤ 0.01; type IIa: p = 0.87,
R2 ≤ 0.01; type IIx: p = 0.78, R2 ≤ 0.01). Data points and bars represent individual donors.
Regression lines indicate the mean ± CI (95%).
R2 ≤ 0.03; C p = 0.11, R2 = 0.16). In addition, the fiber type distribution compared to
the SMI shows no change in favor of one fiber type (Figure 4.6, D type I: p = 0.11, R2
= 0.14; type IIa: p = 0.11, R2 = 0.14; type IIx: p = 0.22, R2 = 0.09).
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Figure 4.6: Change of mean fiber area during aging and fiber type proportion compared
to SMI.
Fibers of each type were measured in size and the average was compared to the SMI of the
given individual. Each patient’s fiber type distribution is displayed as a bar of corresponding
color (fiber type I: green; type IIa: black; type IIx: red). Compared to the skeletal muscle index
no fiber type shows any correlation to its mean area (A p = 0.54, R2 ≤ 0.02; B p = 0.5, R2
≤ 0.03; C p = 0.11, R2 = 0.16). The fiber type proportion shows a heterogeneous distribution
compared to SMI (D, fiber type I: p = 0.11, R2 = 0.14; type IIa: p = 0.11, R2 = 0.14; type IIx: p
= 0.22, R2 = 0.09). Data points and bars represent individual donors. Regression lines indicate
the mean ± CI (95%).
4.7 Physical impairment increases with aging
To estimate physical performance of patients with proximal femoral fractures, we used
three different clinically utilized questionnaires targeting the activities of the daily living.
The score values determined for each individual was then compared to the age and the
SMI. The goal was to detect possible changes of physical impairment with higher age
or lower muscle mass.
The analysis showed, that neither the Barthel index, the parker mobility score nor the
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SARC-F score correlate to the SMI (A p = 0.48, R2 ≤ 0.05; B p = 0.43, R2 ≤ 0.05;
C p = 0.2, R2 = 0.09) (Figure 4.7, A-C). However, while the Barthel index showed no
correlation to the age of the corresponding individual, the parker mobility score and the
SARC-F score values significantly decline with higher age (D p = 0.23, R2 = 0.08; E p
≤ 0.05, R2 = 0.21; F p ≤ 0.05, R2 = 0.31). Thus, we could show that physical fitness
declines with aging, especially in activities that involve the lower extremities (Figure 4.7,
D-F).
Figure 4.7: Correlation of mobility scores to SMI and to age.
The graphs show the comparison of the clinical scores we surveyed to either the SMI (A-C) or
the age (D-F). Neither the Barthel index, the parker mobility score nor the SARC-F score values
correlate to SMI (A p = 0.48, R2 ≤ 0.05; B p = 0.43, R2 ≤ 0.05; C p = 0.2, R2 = 0.09; D p =
0.23, R2 = 0.08). However, the parker mobility score values and SARC-F score values decline
compared to higher age (E p ≤ 0.05, R2 = 0.21; F p ≤ 0.05, R2 = 0.31). Data points represent
individual donors. Regression lines indicate the mean ± CI (95%).
39
Results
4.8 Data of sarcopenic patients does not differ from
data of non-sarcopenic patients
For comparison between sarcopenic and non-sarcopenic patients, we divided the study
population into two groups depending on the measured SMI and low grip strength. As a
reference, we took the definition contributed by the EWGSOP (Cruz-Jentoft et al., 2010)
and thus, patients with a SMI lower than 8.87 kg/m2 and grip strength lower than 30 kg
for men and a SMI lower than 6.42 kg/m2 and grip strength lower than 20 kg for women
were deemed sarcopenic. Patients with higher SMI and grip strength were considered
non-sarcopenic. Hence, per definition the SMI and the skeletal muscle mass between
these two groups were significantly different (p ≤ 0.05). Despite that, we could not find
any difference in the body mass index (p = 0.95). This showed that patients with sar-
copenia do not necessarily weigh less than non-sarcopenic patients but still exhibit a
deficiency of muscle mass (Figure 4.8).
Figure 4.8: Comparison of skeletal muscle mass, body mass index and skeletal muscle
index in non-sarcopenic and sarcopenic patients.
The graphs show the individual data of the overall study group divided into non-sarcopenic
and sarcopenic patients, plotted for total skeletal muscle mass, body mass index and skeletal
muscle index. By definition, the skeletal muscle mass and the SMI are significantly different,
but we could not find any difference in the body mass index between these two groups (C p =
0.95). S-: non-sarcopenic, S+: sarcopenic. Data points represent individual donors. Error bars
represent mean ± SD. * equals p ≤ 0.05.
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We analyzed the values in the physical performance questionnaires and found that
sarcopenic patients did not score significantly worse in either of all three tests (Figure
4.9, A p = 0.45; B p = 0.13; C p = 0.57).
Figure 4.9: Physical performance scores in non-sarcopenic and sarcopenic patients.
The graphs show the individual data of the overall study group and the subdivision into non
sarcopenic and sarcopenic patients, plotted for Barthel index, parker mobility score and SARC
F score. We could find no difference between non sarcopenic and sarcopenic patients in regard
to physical impairment (A p = 0.45; B p = 0.13; C p = 0.57). S-: non-sarcopenic, S+: sarcopenic.
Data points represent individual donors. Lines represent mean ± SD.
Additionally, we investigated the fiber type proportion and fiber size of all study par-
ticipants to comprehend, if any difference that might be correlated to the occurrence of
sarcopenia exists. Looking at the mean fiber area, the striking difference in size be-
tween type I and type IIa and IIx fibers is also present in sarcopenic patients and thus
does not differ from the overall population. Concordant to that, there is no difference
between the mean fiber area of non-sarcopenic and sarcopenic patients (Figure 4.10,
A type I: p = 0.64; type IIa: p = 0.75; type IIx: p = 0.93). By comparing the fiber type
proportion in the two groups, we could not find any significant difference for neither type
I, IIa nor IIx fibers (Figure 4.10, B type I: p = 0.16; type IIa: p = 0.46; type IIx: p = 0.06).
Although people with sarcopenia exhibit a lack of muscle mass, we could neither as-
sociate this deficiency with generally smaller fibers nor with a lack of one specific fiber
type such as fast twitching type II fibers.
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Figure 4.10: Comparison of mean fiber area and fiber type proportion of type I, IIa and
IIx fibers in non-sarcopenic and sarcopenic patients.
The graphs show the individual data of the overall study group and divided into non sarcopenic
and sarcopenic patients, plotted mean fiber area and fiber type proportion, each divided into
type I (green), IIa (black) and IIx (red) fibers. In comparison, the mean fiber area of all three
fiber types was not significantly different between the two groups (A fiber type I: p = 0.64; type
IIa: p = 0.75; type IIx: p = 0.93). Additionally, fiber type proportion of all three fiber types was
also not significantly different between non sarcopenic and sarcopenic patients (B fiber type I: p
= 0.16; type IIa: p = 0.46; type IIx: p = 0.06). S-: non-sarcopenic, S+: sarcopenic. Data points
represent individual donors. Error bars represent the mean ± SD.
Furthermore, we analyzed if the deficiency of muscle mass might be related to
changes in blood levels of markers that are frequently used for diagnostics of muscle
and bone diseases, such as 25(OH)D, TSH, total protein and calcium. The comparison
between non-sarcopenic and sarcopenic patients revealed that blood levels of all the
measured parameters did not differ from each other. (Figure 4.11, A p = 0.47; B p
= 0.54; C p = 0.23; D p = 0.25). Altogether, the two groups of patients with sarcope-
nia and without did only differ, as per definition, in the SMI and the skeletal muscle mass.
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Figure 4.11: Blood levels of 25(OH)D, TSH, total protein and calcium in non-sarcopenic
and sarcopenic patients.
The graphs show the individual data of the overall study group and divided into non sarcopenic
and sarcopenic patients, plotted for 25(OH)D, TSH, total protein and calcium. Between non
sarcopenic and sarcopenic patients, the comparison of the blood levels showed no significant
difference in neither 25(OH)D (A p = 0.47), TSH (B p = 0.54), total protein (C p = 0.23) nor
calcium (D p = 0.25). S-: non-sarcopenic, S+: sarcopenic. Data points represent individual
donors. Error bars represent the mean ± SD.
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Discussion
To contribute to the still ongoing discussion regarding the causes and onset of sarcope-
nia with the aim of a characterization of this phenomenon, we investigated the role of
muscle weakness in postural muscles, in particular in geriatric people with osteoporotic
bone fractures. In this study, we systematically investigated the differences of fiber type
proportion between sarcopenic and non-sarcopenic patients hospitalized for proximal
femur fractures and compared them to clinical and biochemical markers. The impact of
sarcopenia as an economical and health burden is of increasing interest and has been
shown to be of even more importance in the future. To our best knowledge, there has
not yet been any study investigating the morphological differences in gluteus medius
muscle of both patient groups.
5.1 Skeletal muscle morphology in aging
Our analysis of gluteus medius muscle in the elderly showed that slow-twitching type I
fibers were generally larger than fast-twitching type IIa and IIx fibers and type I fibers
that were predominantly present within the muscle biopsies. As gluteus medius mus-
cles are essentially used for leg and hip stability while being upright standing or walking,
a high amount of type I fibers was expected. Nevertheless, the variance in the amount
of type IIa (11.84± 9.64%) and IIx (9.02± 8.98%) fibers was high throughout all partic-
ipants and thus we compared, in addition to the fiber type, the fiber size and proportion
to age and SMI. We could show a negative correlation between the size of type IIa
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fibers and IIx fibers and age, but not between type I fibers and age. These findings
are consistent with current literature about other lower limb muscles in humans (Ani-
ansson et al., 1986). We hypothesized that with progressed atrophy of fast-twitching
fibers during aging, the share of the different fiber types within gluteus medius muscle
would shift towards a higher proportion of type I fibers. However, unlike in fiber size,
we could not show any differences in fiber type proportion compared to age. The great
variance between each individual and the relatively low sample size made a compari-
son of skeletal muscle fiber morphology hardly possible. We therefore concluded that
if atrophy of fast-twitching fibers would promote a proportional shift of fiber types, either
more participants would have to be examined to even out the variance or participants
would have to be reexamined in a longitudinal study for inter-individual comparison.
Additionally, the muscle biopsies were very small compared to the whole muscle. It is
possible, that the distribution of muscle fibers is not homogenous throughout the mus-
cle and analyzing smaller sections of a muscle can contribute to a higher variance.
Nevertheless, the comparison of muscle fiber size versus age was already investigated,
which showed that the cross-sectional area of skeletal muscle fibers shrinks with in-
creasing age, and especially fast-twitching fibers are shown to be affected (Lexell et al.,
1983; Lexell, 1995). As the significant loss of muscle mass is one of the main features
that characterizes sarcopenia, we compared muscle fiber size to SMI. We hypothesized
that participants with a higher SMI exhibit generally larger muscle fibers and, because
fast-twitching fibers are shown to be more affected by atrophy in age, participants with
a higher SMI also exhibit a higher proportion of type IIa and IIx fibers. This proved to
be wrong, as neither type I, IIa nor IIx fiber size correlates to SMI and additionally, SMI
does not correlate to the proportion of either fiber type. This led us to the conclusion,
that while SMI does have a somewhat predictive value in clinical settings, because it
correlates to poor health outcomes in patients with sarcopenia (Janssen et al., 2004),
it does not give any information about the fiber type composition.
Furthermore, it has been shown that muscle fiber atrophy in aging muscles preferen-
tially affects fast-twitching fibers (Lexell et al., 1988; Coggan et al., 1992). Causes for
this phenomenon have yet to be elucidated, but it is theorized that both muscle fiber
metabolism as well as the neuronal innervation play important roles in this process.
Aare et al. discovered that repeated cycles of denervation and reinnervation in young
(eight month) and very old (35 month) rats leads to fiber type grouping (Aare et al.,
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2016). Additionally, very old rats showed a decreased ability to reinnervated muscle
fibers, which results in further atrophied fibers. In our study cohort we observed that
half of the participants depicted bundling of type I fibers to some extent, which is pre-
sumably either due to an increased atrophy of fast-twitching fibers or due to loss of
innervation by the motor neuron and subsequent reinnervation by other motor neurons.
Spatio-temporal analysis of ALS progression in superoxide dismutase 1 (SOD1) gene
mutant mouse model, which is used to induce clinical weakness through the loss of
motor neurons, suggests that this motor neuron disease begins at the distal end of
the axons in a “dying-back” pattern (Fischer et al., 2004; Tintignac et al., 2015). Fur-
thermore, the authors concluded that these distal pathological mechanisms in motor
neurons are responsible for fiber type grouping. Our findings depicted bundling of mus-
cle fibers, which underlines the involvement of motor neuron adaptation and potential
axonal pathologies in the genesis of sarcopenia. These findings are emphasized by
Piasecki et al., who found that the size of motor units (i.e. the number of muscle fibers
innervated by one motor neuron) of older people is significantly lower than that of a
young control group (Piasecki et al., 2016). They also hypothesized that changes in
motor units prelude future impairment in physical fitness and might therefore be of inter-
est in early diagnostics. Comparable results were found by Drey et al., who discovered
that a significant amount of sarcopenic patients depicted pathologic motor unit number
indices in hypothenar (Drey et al., 2014).
Fast-twitching muscle fibers need high energy resources, while conducting fast move-
ments. With advanced age, resources and efficient energy yield are significantly less
productive (Layec et al., 2015), which could possibly lead to alimentary difficulties re-
garding fast-twitching fibers. This has especially been demonstrated in the demand of
ATP for fast dynamic contractions, which was significantly higher in older adults com-
pared to young adults (Layec et al., 2018, 2016). Additionally, older people are likely
to be more sedentary than younger people. As a sedentary lifestyle probably depends
more on stable and slow than on fast movements, fast-twitching fibers are likely to
be less stimulated than slow fibers. This lack of stimulus can also promote advanced
degradation compared to activated fibers (Mosole et al., 2016). Both less productive
energy output and sedentary lifestyle are possible causes for fiber type bundling.
In sum, these results underline that for complete understanding of muscle mass and
strength loss, the neuromuscular fidelity should be investigated, contrary to only mus-
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cle or neuronal tissue alone.
5.2 Morphological differences between sarcopenic and
non-sarcopenic patients
To evaluate a potential sarcopenia-dependent effect onto skeletal muscle morphology,
physical function and biochemical markers, we divided the study population into healthy
and sarcopenic patients. While it was shown that muscle fiber size, especially of fast-
twitching fibers generally decline with age, we hypothesized that fast-twitching fibers
are even more affected in people with sarcopenia than in healthy patients. However,
we could not show any correlation between sarcopenia and either fiber size or fiber
proportion within the muscle biopsies for any of the three examined fiber types. The
proportion of type IIa and type IIx fibers were generally low in all participants, which
makes it even more difficult to detect possible changes in fiber area. Predominant
changes in fast-twitching fibers would therefore be of lesser consequence. Addition-
ally, the reason for the dominance in proportion of type I fibers is not known. Both more
dominant atrophy of fast-twitching fibers and denervation due to atrophy of motor neu-
rons with subsequent reinnervation pose possible explanations (Rowan et al., 2012).
Each of those factors might represent independent mechanisms that lead to a shift of
fiber types towards slow-twitching fibers. Additionally, we pooled all non-sarcopenic
and sarcopenic patients in two groups but did not correct for age. This might also rep-
resent a confounding variable, as age itself is correlated to increased fiber atrophy and
must therefore be considered when comparing these two groups.
5.3 Physical performance of the elderly
Along with the muscle fiber size, we assessed the physical function with questionnaires
concerning independent abilities in day-to-day living and compared the obtained scores
with age and SMI. We proposed that the study cohort would exhibit a negative corre-
lation between physical function and age, as well as the muscle mass, which would
affect strength and therefore lead to physical impairment. According with the already
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published data that physical function declines with age (Frontera et al., 2008; Novak,
1972; Sathyaprabha, 2000; Tanaka et al., 2017), elderly patients of our cohort scored
lower values compared to younger patients. Malmstrom et al. developed the five-item
SARC-F questionnaire, which assesses the main features or consequences of sarcope-
nia (Malmstrom et al., 2016). They designed the test to reflect an approximation of the
physical ability. In fact, the SARC-F score is correlated to physical performance and
likelihood of hospitalization. Similarly, the Parker-mobility score is designed to provide
an estimation of mortality after hip fractures and the Barthel index provides an estimate
of physical impairment (Parker and Palmer, 1993; Mahoney and Barthel, 1965). How-
ever, the Parker-mobility score and the SARC-F score are age-dependent, whereas the
Barthel index is not age-specifically validated. A possible explanation for this could
be that the Parker-mobility score and the SARC-F score are devised to screen for dis-
abilities in lower extremity strength, which affects walking and climbing stairs and the
Barthel index is a questionnaire to assess whole body mobility in terms of self-care,
which predominantly focuses on upper body mobility and continence (Mahoney and
Barthel, 1965; Parker and Palmer, 1993; Malmstrom et al., 2016). For example, a per-
son in a wheelchair with unrestricted mobility and strength in the upper body can score
relatively high in the Barthel index compared to parker-mobility and SARC-F score.
Loss of strength could therefore be initially noticeable in those questionnaires focus-
ing on postural movements and stability. Nonetheless, we could not proof any relation
between mobility scores and relative skeletal muscle mass, as neither Barthel index,
parker-mobility score nor SARC-F score correlate to SMI.
We utilized all three tests to assess the physical function of the participants. However,
we could not find any differences in the scored values of each questionnaires between
sarcopenic and non-sarcopenic patients. Thus, we conclude that although the ques-
tionnaires are validated in predicting health outcomes, they do not represent a proper
replacement for physical performance tests, due to their retrospective and subjective
character.
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5.4 Study design and methodology
In this study, we analyzed biopsies, clinical and biochemical data of 20 patients. Of
those four were sarcopenic, with all but two patients, all were above 69 years old, which
yields limitations in the possible interpretation of the results. The low number of par-
ticipants can only give a rough estimate of sarcopenia prevalence in the population,
which could otherwise evaluate the eventual robustness of the definition provided by
the EWGSOP. In addition, the study cohort consists of only people with proximal femur
fractures, hence, only people with traumatic injuries presumably due to weakness in
postural skeletal muscle were included. As there was no control group without proximal
femur fractures available, the differences between those two groups, and a possible
impact of muscle morphology on postural instability, could not be further evaluated.
Furthermore, with the average age of 79.6 ± 10.4 years, the cohort consisted mainly of
elderly patients. This lack of young patients as a control groupmade a possible compar-
ison of aging skeletal muscle to younger skeletal muscle particularly regarding normal,
physiological morphological changes, in contrast to possible magnified changes by rea-
son of sarcopenia, unfeasible.
Gluteus medius muscle inherits important functions in postural stability by stabilizing the
femur and pelvis, which makes it interesting to investigate sarcopenia and age-related
effects in regard to potential risks for falls. The amount of fast-twitching type IIa and IIx
fibers is relatively low throughout all participants. Possible changes in size and num-
ber of type II fibers through age or sarcopenia, might have a mild influence on physical
performance, as the relative proportion of those fast-switching fibers is low. Therefore,
the effect of sarcopenia on fiber type composition could be more severe than expected,
either higher or lower. In addition, we could show that the variance in proportion of fiber
types within the muscle biopsy and throughout the individuals is distinctively exalted.
Comparing biopsies yields a highly heterogeneous picture of gluteus medius muscle,
which complicates synthesis of a general statement about the influence of age and sar-
copenia on skeletal muscle fibers.
Grip strength is a widely accepted measurement of skeletal muscle strength, espe-
cially in the context of sarcopenia, as it correlates to general muscle strength and is
a good predictor of disability and mortality in older people (Newman et al., 2006; Roh
et al., 2017). Nevertheless, even if grip strength is an established marker for muscle
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strength, the direct correlation to morphological markers of gluteus medius biopsies
must be proven. As all our participants were hospitalized for proximal femur fracture,
we were unable to effectively measure gluteus medius strength. Therefore, we resorted
to use grip strength as a criterion for the presence of sarcopenia. To estimate physi-
cal function, a questionnaire was used that consisted of the Barthel index, the parker
mobility score and the SARC-F score. All of these are designed to screen for disabili-
ties in activities of the daily living and to predict long-term mortality. However, they do
not make a direct statement on the actual physical function of the respondent, in con-
trast to short physical performance battery or gait speed. Furthermore, a confounding
variable is the non-objectivity of questionnaires. Patients asked about their ability to
conduct activities of day-to-day living might falsely answer questions through wrong-
ful self-perception (personal communication with Pascal Martin). However, it has been
shown that especially the SARC-F score has been proven to successfully screen for
sarcopenia (Malmstrom et al., 2016), but is arguably useful in replacing objective phys-
ical performance tests.
5.5 Sarcopenia: Validation of definition and diagnos-
tics
Our goal with this study was to investigate structural characteristics, especially fiber size
and proportion, in gluteus medius muscle of sarcopenic and non-sarcopenic patients.
This should result in an appropriate answer to the question whether sarcopenia is a
form of physiological aging, a disability or even a disease. Our study revealed that loss
of strength and hence sarcopenia, is not associated with morphological changes in glu-
teus medius muscle. We could not find differences between the two groups in neither
muscle fiber morphology, physical performance nor blood levels of TSH, 25(OH)D, total
protein or calcium, which makes sarcopenic patients in our study indistinguishable from
other patients in those terms. Nevertheless, it was proven that sarcopenia is associ-
ated to higher risk of poor health outcomes and higher mortality (Newman et al., 2006;
Visser et al., 2000; Beaudart et al., 2017).
Furthermore, sarcopenia is not only a product of continuous denervation and fiber atro-
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phy during aging, but also includes various other causes like nutrition intake (Volpi et al.,
2003), missing physical exercise (Trappe et al., 2004), chronic inflammation (Bano et al.,
2017) and endocrine influences (Ng et al., 2018). Examples of themultitude of influence
factors on muscle wasting are diseases that depict these causes to a significant degree
and are not exclusively observed in older people. Examples of such diseases are ALS
and Cushing’s disease, which both lead to a loss of muscle mass and strength, although
through either the death of motor neurons or an increased catabolic metabolism due to
increased levels of glucocorticoids, respectively. To this date, it is not fully clear what
contributes to increased muscle wasting and if it is possible to find a single main cause
for sarcopenia that affects each patient. Nevertheless, we excluded patients with severe
comorbidities in this study and therefore eliminated patients with muscle wasting due
to other diseases. We concluded that because of no apparent diseases of the study
cohort and no obvious differences between sarcopenic and non-sarcopenic patients,
the cause for muscle wasting must lie in the multitude of subtle factors that in sum neg-
atively affect muscle mass and strength. The differentiation between individuals with no
evident cause and those where a clear single cause can be isolated is likewise found in
conditions such as osteoporosis, dementia or high blood pressure and is therefore noth-
ing new to clinical medicine. As Crutz-Jentoft et al. already pointed out in their review
on sarcopenia, it might be beneficial for clinical practice that sarcopenia is categorized
into a primary and secondary form (Cruz-Jentoft et al., 2010). Primary sarcopenia in-
cludes all elderly patients with no direct cause and is therefore considered age-related
and secondary sarcopenia includes all patients with one or more obvious evidences.
Cruz-Jentoft et al. defined a consensus, which diagnostic tools should be utilized for
clinical diagnosis. Muscle mass can either be assessed by dual energy X-ray absorp-
tiometry (DXA) or BIA, physical performance via short physical performance battery or
gait speed and grip strength via hand dynamometer. The availability of the different
tools makes diagnostic procedure easier, due to the availability of at least one of these
tools. It has been shown that DXA and BIA do not necessarily yield the same results
in analyzing skeletal muscle mass (Reiss et al., 2016). The authors implied, that an
estimated one out of six patients are misdiagnosed with sarcopenia, when using BIA
compared to classification using DXA. However, this does not imply that either BIA or
DXA is a better approach for determining skeletal muscle mass, but that there is still no
consistency throughout the applied technique. These facts are one of the reasons that
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block the progression towards a common diagnosis.
Furthermore, different studies implying slightly different thresholds. For muscle mass
assessed by a BIA, there are two sets of cutoffs defined: Chien et al. defined low skele-
tal muscle mass as two standard deviations below the mean muscle mass of a young
control group in Taiwanese subjects (Chien et al., 2008). Janssen et al. estimated
skeletal muscle mass by a BIA in a cohort consisting of subjects being 60 years and
above and defined cutoff values associated with the risk of physical disability (Janssen
et al., 2004). Defining the skeletal muscle cutoff as two standard deviations below the
mean of a young control group depicts the major drawback that by comparing aging
people with a young group, eventually every patient would be deemed sarcopenic re-
gardless of actual physical disabilities. In contrary, the approach by Janssen et al.
appears to be much more plausible as patients are compared with a cohort of the same
age. Nevertheless, this approach is based on a generally smaller group size as they
firstly compared skeletal muscle mass to the likelihood of disabilities. This means that
the thresholds are not as robust as the cutoff values by Chien et al. and therefore need
further investigation. Additionally, Visser et al. compared both muscle mass and mus-
cle strength with lower-extremity performance and could show that only leg extensor
strength was independently associated with lower-extremity performance (Visser et al.,
2000). Furthermore, it has been shown that lower extremity muscle and fat mass are
no significant risk factors for disabilities and mortality (Cesari et al., 2009). Although
this seems to contradict the findings of Janssen et al. that SMI is correlated to the
likeliness of disabilities, it could be possible that the skeletal muscle mass might be as-
sociated with physical fitness, albeit probably dependently. Using skeletal muscle mass
as the main criterion in the definition of sarcopenia seems therefore questionable, as
the clinical relevance of this parameter is not out of question and strength and physical
performance depict a more robust association with poor health outcomes.
In sum, Cruz-Jentoft et al. provide several methods per criterion and several thresh-
old values based on different studies for each of all the three criteria, namely muscle
mass, strength and physical performance, which implies that this clinical definition of
sarcopenia can hardly be considered a consensus. We propose sarcopenia to be de-
fined clinically by the loss of strength and/or physical performance, shifting the picture
towards a disability, independent from the definite cause in a certain individual. Differen-
tiating between primary and secondary sarcopenia might lead to different approaches
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in clinical management.
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Conclusion & Outlook
We could not find morphological or biochemical differences between sarcopenic and
non-sarcopenic patients with proximal femur fractures. We excluded any patient with
severe comorbidities, and thus only included patients with primary sarcopenia. Con-
cordant to the clinical definition of sarcopenia by the EWGSOP, we conclude that it is
necessary to divide sarcopenia into primary and secondary sarcopenia, depending on
the presence of distinguishable causes. Nevertheless, the definition provided by EWG-
SOP is not yet consistent in itself, as they present more than one threshold level for each
criterion. For this purpose, we propose that the given thresholds should be reevaluated
with the aim of generating a robust and universal definition of sarcopenia. Additionally,
the focus of sarcopenia should be shifted towards muscle strength and physical per-
formance as the driving parameters, as they are directly associated with poor health
outcomes.
Future goals should include the derivation of a more robust definition of sarcope-
nia for clinical application, as well as the investigation of different influence factors on
muscle wasting both in young and aging humans. For this purpose, strength and physi-
cal performance need to be measured throughout a large population cohort to estimate
age-dependent threshold levels. This is a necessary step to compare the functional pa-
rameters with the population of the same age. As those parameters decline with age,
comparison with young control groups would therefore inevitably lead to false positive
diagnoses. Additionally, a new definition of sarcopenia should then be discussed, with
the main criteria being strength and physical performance of the whole body and not
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just individual muscles.
Sarcopenia is a geriatric syndrome due to a multitude of causes. Loss of muscle mass
and strength in aging is not yet fully understood. Investigating the age – and disease-
related effects leading to muscle wasting are therefore needed to understand the bio-
chemical pathways that lead to sarcopenia. Eventually, biomarkers could be available
to differentiate between different causes for muscle wasting and could help in the early
diagnostics of sarcopenic patients. For this, various diseases associated with a sig-
nificant loss of skeletal muscle can be used as model systems to better understand
the various pathophysiological mechanisms. The economical and sanitary burden sar-
copenia poses is conspicuous and is expected to aggravate within the next decades.
To effectively address this problem, sarcopenia should be treated as early as possible.
Therefore, it is necessary to devise a prevention plan to reach out for people and moti-
vate them to obtain a more active lifestyle by exercising on a regular basis, as physical
activity is the only treatment known to this date that effectively improves fitness and
preserves mobility in age.
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Table 7.1: Overview of collected data.
Donor Height
[cm]
Weight
[kg]
Age
[years]
Barthel
index
Parker
mobility
score
SARC-F
score
Handgrip
[kg]
D01 169 90 76 100 9 1 22.9
D02 168 60 69 85 6 6 32.5
D04 170 42 81 90 5 6 9.9
D05 171 69 92 80 6 8 13.0
D08 160 70 92 95 4 7 11.3
D09 168 65 76 95 7 2 21.7
D10 153 48 80 100 5 3 20.4
D11 157 67 81 95 7 5 12.8
D13 168 57 80 100 9 1 17.0
D14 180 56 90 ND ND ND 34.7
D15 184 105 55 100 9 0 50.0
D17 160 58 92 95 7 3 15.4
D18 152 50 93 95 5 5 15.0
D19 175 70 75 95 6 4 20.7
D20 163 68 85 75 6 5 11.3
D21 154 50 81 100 9 2 13.2
D22 164 52 87 100 9 1 14.3
D23 169 75 69 100 9 1 31.3
D24 190 80 59 100 9 1 37.6
D25 180 80 78 ND ND ND 13.9
ND = not determined.
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Donor 25(OH)D
[ng/ml]
TSH
[mU/l]
Total
protein
[g/l]
Calcium
mmol/l
Resistance
[Ω]
SMM
[kg]
SMI
[kg/m2]
SMM
pro-
portion
[%]
D01 10.0 1.45 6.0 2.03 409.1 27.70 9.70 30.78
D02 10.0 1.63 5.9 1.99 475.1 27.85 9.87 46.42
D04 13.8 1.47 5.2 2.03 521.1 21.59 7.47 51.41
D05 15.1 1.64 6.0 2.15 534.7 20.50 7.01 29.71
D08 16.9 2.76 5.2 2.26 524.7 18.13 7.08 25.91
D09 10.0 1.24 4.9 1.88 507.2 22.02 7.80 33.88
D10 15.4 1.26 5.2 1.94 391.1 23.42 10.01 48.80
D11 14.4 2.25 5.0 2.18 723.0 13.02 5.28 19.44
D13 18.5 1.32 5.4 2.02 589.3 18.63 6.60 32.68
D14 16.7 1.41 5.2 ND 427.2 32.95 10.17 58.84
D15 ND 1.97 5.5 ND 459.2 34.59 10.22 32.94
D17 ND 2.62 5.2 ND 413.9 23.37 9.13 40.30
D18 11.8 1.08 5.2 1.98 498.8 17.07 7.39 34.15
D19 60.2 0.47 4.8 2.13 463.3 26.28 8.58 37.55
D20 ND 0.54 5.1 2.08 513.6 19.81 7.46 29.13
D21 19.8 ND 5.8 2.04 629.5 14.46 6.10 28.92
D22 10.0 0.16 6.3 2.10 658.8 15.30 5.69 29.42
D23 10.0 1.22 4.2 1.84 414.7 27.82 9.74 37.09
D24 10.0 0.81 6.0 2.11 516.1 32.79 9.08 40.98
D25 10.0 0.40 5.8 2.04 513.4 28.70 8.86 35.87
ND = not determined.
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Fiber number Fiber proportion mean Fiber size [μm2]
Donor Type
I
Type
IIa
Type
IIx
Sum Type
I %
Type
IIa %
Type
IIx %
type I
area
type
IIa
area
type
IIx
area
D01 646 288 157 1091 0.592 0.264 0.144 8244 5650 2681
D02 1736 36 264 2036 0.853 0.018 0.130 7663 2297 2492
D04 2946 382 196 3524 0.836 0.108 0.056 2299 3362 2108
D05 4061 2507 2388 8956 0.453 0.280 0.267 6093 2198 1199
D08 2219 8 20 2247 0.988 0.004 0.009 5508 1435 1074
D09 1964 117 17 2098 0.936 0.056 0.008 3357 1560 1306
D10 2309 117 33 2459 0.936 0.056 0.008 7053 1031 1149
D11 2306 13 5 2324 0.992 0.006 0.002 6866 2034 1375
D13 3041 402 544 3987 0.763 0.101 0.136 7668 3463 2746
D14 1026 309 545 1880 0.546 0.164 0.290 1946 1110 1213
D15 1349 847 558 2754 0.490 0.308 0.203 6020 6047 4450
D17 1946 754 124 2824 0.689 0.267 0.044 4658 1611 1452
D18 3059 459 748 4266 0.717 0.108 0.175 7940 1889 1504
D19 4642 578 0 5220 0.889 0.111 0.000 2271 1001 ND
D20 1417 0 0 1417 1.000 0.000 0.000 4698 ND ND
D21 3225 39 283 3547 0.909 0.011 0.080 11312 4223 3221
D22 1568 312 80 1960 0.800 0.159 0.041 2958 2790 1074
D23 1249 228 279 1756 0.711 0.130 0.159 6562 1990 1947
D24 4721 305 0 5026 0.939 0.061 0.000 4083 3454 ND
D25 1114 238 68 1420 0.785 0.168 0.048 4304 1990 1947
ND = not determined.
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Figure 7.1: Measurement of handgrip strength.
We measured handgrip strength in all participants and compared them to both age and SMI.
We found that with increasing age skeletal muscle strength significantly decreases (A p ≤ 0.05,
R2 = 0.57). Additionally, handgrip strength positively correlated to relative muscle mass (B p
≤ 0.05, R2 = 0.51). This implies that muscle mass is at least indirectly correlated to muscle
strength. Data points represent individual donors. Female: red, male: blue. Regression lines
indicate mean ± CI (95%) of the whole study cohort.
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Figure 7.2: COX/SDH staining.
The figure shows COX/SDH stained cross-sections of 4 individuals representing the study co-
hort. We analyzed mitochondrial function in skeletal muscle biopsies of all participants. Most
participants showed close to or only negative fibers (brown). Positive muscle fibers with mito-
chondrial dysfunction were very rare throughout all participants (blue, black arrow head). Scale
bar = 200 μm.
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Appendix
Abbreviations
25(OH)D 25-hydroxyvitamin D
AChR acetylcholine receptor
ADP adenosine diphosphate
ALS amyotrophic lateral sclerosis
ATP adenosine triphosphate
ATPase adenosine triphosphatase
BIA bioelectrical impedance analysis
BMI body mass index
CI confidence interval
CSA cross-sectional area
COX/SDH cytochrome c oxidase/succinate dehydrogenase
DAPI 4’,6-diamidino-2-phenylindole
DGC dystrophin-associated glycoprotein complex
DHPR dihydropyridine receptor
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DXA dual energy X-ray absorptiometry
etc. et cetera
EWGSOP European Working Group on Sarcopenia
MHC myosin heavy chain
mtDNA mitochondrial DNA
PBS phosphate buffered saline
PBS-T phosphate buffered saline with 0,1% Triton
Pi inorganic phosphate
ROS reactive oxygen species
RyR ryanodine receptor
SD standard deviation
SERCA sarco/endoplasmatic reticulum calcium-ATPase
SMI skeletal muscle index
SMM skeletal muscle mass
SOD1 superoxide dismutase 1
TSH thyroid stimulating hormone
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